Ideaya Biosciences Inc (IDYA) - Total Assets
Based on the latest financial reports, Ideaya Biosciences Inc (IDYA) holds total assets worth $1.31 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ideaya Biosciences Inc - Total Assets Trend (2017–2025)
This chart illustrates how Ideaya Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Also see Ideaya Biosciences Inc (IDYA) total market value for the company's overall valuation and market capitalisation.
Ideaya Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Ideaya Biosciences Inc's total assets of $1.31 Billion consist of 60.1% current assets and 39.9% non-current assets. Review how much debt does Ideaya Biosciences Inc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.2% |
| Accounts Receivable | $5.97 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Ideaya Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See IDYA share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ideaya Biosciences Inc's current assets represent 60.1% of total assets in 2025, a decrease from 77.7% in 2017.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2025, down from 34.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Ideaya Biosciences Inc Competitors by Total Assets
Key competitors of Ideaya Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Ideaya Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.45 | 12.39 | 6.96 |
| Quick Ratio | 10.45 | 12.39 | 6.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $781.35 Million | $630.26 Million | $230.33 Million |
Ideaya Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Ideaya Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.13 |
| Latest Market Cap to Assets Ratio | 3.28 |
| Asset Growth Rate (YoY) | -1.3% |
| Total Assets | $1.11 Billion |
| Market Capitalization | $3.63 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ideaya Biosciences Inc's assets at a significant premium (3.28x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Ideaya Biosciences Inc's assets decreased by 1.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Ideaya Biosciences Inc (2017–2025)
The table below shows the annual total assets of Ideaya Biosciences Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.11 Billion | -1.31% |
| 2024-12-31 | $1.12 Billion | +73.12% |
| 2023-12-31 | $649.32 Million | +67.36% |
| 2022-12-31 | $387.97 Million | +1.74% |
| 2021-12-31 | $381.35 Million | +27.85% |
| 2020-12-31 | $298.27 Million | +163.95% |
| 2019-12-31 | $113.00 Million | +17.05% |
| 2018-12-31 | $96.54 Million | +452.33% |
| 2017-12-31 | $17.48 Million | -- |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and … Read more